Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

399
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
399
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

495
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
495
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.5K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.5K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

799
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
799
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

518
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
518
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

815
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
815

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCAS-3 is required for the progression of autophagosome formation to degrade paternal mitochondria in <i>Caenorhabditis elegans</i>.

iScience·2026
Same author

Sarcomatoid Transformation of Pulmonary Mucinous Adenocarcinoma as a Mechanism of Immunotherapy Resistance.

Thoracic cancer·2026
Same author

Anti-cancer therapy and the exacerbation of pulmonary nontuberculous mycobacterial infection.

Respiratory investigation·2026
Same author

Inhalation of hydrogen gas reduces exacerbations of acute aortic dissection in mice.

Life sciences·2026
Same author

Germ granule components regulate endosomal switching during the oocyte-to-embryo transition in Caenorhabditis elegans.

Communications biology·2026
Same author

Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective study.

Scientific reports·2026

Related Experiment Video

Updated: Dec 18, 2025

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
12:41

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat

Published on: August 28, 2021

4.7K

Dexmedetomidine for dyspnoea.

Akiko Mano1, Tomohiro Murata2, Kazuma Date2

  • 1Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan akiko_mano@tmghig.jp.

BMJ Supportive & Palliative Care
|June 13, 2020
PubMed
Summary

Dexmedetomidine, a selective α2-adrenoreceptor agonist, effectively managed dyspnoea in a terminally ill patient with pulmonary haemorrhage. This case highlights its potential in palliative care for managing severe respiratory symptoms.

Keywords:
dyspnoeasupportive careterminal care

More Related Videos

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.3K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.4K

Related Experiment Videos

Last Updated: Dec 18, 2025

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
12:41

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat

Published on: August 28, 2021

4.7K
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.3K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.4K

Area of Science:

  • Anesthesiology
  • Palliative Care
  • Critical Care Medicine

Background:

  • Dexmedetomidine is a selective α2-adrenoreceptor agonist known for sedation, analgesia, and anxiolysis.
  • It is increasingly used as a first-line sedative in intensive care units, often replacing traditional agents like benzodiazepines.
  • The application of dexmedetomidine in palliative care settings, particularly for symptom management in terminally ill patients, remains under-recognized.

Purpose of the Study:

  • To report a case of successful dyspnoea management in a terminally ill patient using dexmedetomidine.
  • To explore the potential utility of dexmedetomidine in palliative care for managing refractory symptoms.

Main Methods:

  • A case report detailing the clinical experience with a terminally ill patient experiencing uncontrollable pulmonary haemorrhage and severe dyspnoea.
  • The patient was on mechanical ventilation and received continuous intravenous oxycodone.
  • Dexmedetomidine was administered as an adjunct therapy to manage dyspnoea.

Main Results:

  • Dexmedetomidine, in conjunction with intravenous oxycodone, successfully alleviated the patient's severe dyspnoea.
  • The intervention allowed for effective symptom control in a patient with a life-limiting condition.

Conclusions:

  • Dexmedetomidine can be a valuable option for managing severe dyspnoea in terminally ill patients, even in the context of critical conditions like pulmonary haemorrhage.
  • Further research is warranted to establish the role and safety of dexmedetomidine in palliative and end-of-life care.